Intermittent Fasting for Pancreatic Cancer Risk

FM
Overseen ByFlorencia McAllister, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.

Who Is on the Research Team?

FM

Florencia McAllister, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

* Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
I have a genetic mutation or syndrome that increases my risk for pancreatic cancer.
I have a family history of pancreatic cancer.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants follow an intermittent fasting regimen, fasting for 16 consecutive hours each day with an 8-hour eating window

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, including changes in biological markers

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Intermittent Fasting

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Intermittent fastingExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+